CRO

Simplified Clinical rolls out AI text analytics addition to its platform

Viz.Ai
Simplified also plans to add other new technologies to the platform, including Microsoft’s Power BI.

Clinical trial software provider Simplified Clinical hasĀ added AI-supported text analytics to its platform to improve data collection and insights.

The Portsmouth, New Hampshire-based company said users of its Clinical Discovery Platform will be able to access unstructured medical texts, allowing them to identify relevant keywords and phrases, make better connections, compile statistics and streamline data analysis.

Simplified also plans to add other new technologies to the platform, including Microsoft’s Power BI data visualization softwareĀ and automated data capture via FHIR, the acronym for fast healthcare interoperability resources that is a standard for how healthcare information can be exchanged between different computer systems regardless of how it is stored.

ā€œTechnological advancements like AI and text analytics are making it faster, more accurate, and more effective to move clinical trial approvals forward,ā€ Simplified's CEO John SchwopeĀ said in an Oct. 10Ā release.Ā ā€œResearchers can use this tool to quickly and accurately read doctors’ notes, minimize risk and avoid regulatory hurdles.ā€

The use of AI to crunch vast amounts of data in order toĀ fine-tuneĀ clinical studies from design and recruitment toĀ post-trial follow-up has been rapidlyĀ embraced by parts of theĀ industry.

Earlier this month, Healthcare platform company H1Ā announced it was delving deeper into the use of machine learning by adding GenosAI to its clinical trials arm, Trial Landscape. The company said users will be able to pose questions that GenosAIĀ canĀ respond to with the aid of natural language processing, such as inquiring about the best-performing trial sites or suitable locations for a particular disease area.Ā 

In August, computational imaging company Altis LabsĀ said it was leading anĀ international project that includes drug giants AstraZeneca and Bayer to advance the use of "digital twins" in clinical trials. Digital twins are AI simulations that help drug developers and clinicians understand how a patient or a therapy may perform in real-life situations.